APA aipamena

Kang, S., Keam, B., Ahn, Y., Park, H., Kim, M., Kim, T. M., . . . Heo, D. S. (2018). Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma. Oncoimmunology.

Chicago Style aipamena

Kang, Seong-Ho, Bhumsuk Keam, Yong-Oon Ahn, Ha-Ram Park, Miso Kim, Tae Min Kim, Dong-Wan Kim, and Dae Seog Heo. "Inhibition of MEK With Trametinib Enhances the Efficacy of Anti-PD-L1 Inhibitor By Regulating Anti-tumor Immunity in Head and Neck Squamous Cell Carcinoma." Oncoimmunology 2018.

MLA aipamena

Kang, Seong-Ho, et al. "Inhibition of MEK With Trametinib Enhances the Efficacy of Anti-PD-L1 Inhibitor By Regulating Anti-tumor Immunity in Head and Neck Squamous Cell Carcinoma." Oncoimmunology 2018.